title: Upcoming therapies for heart failure.
abstract: Treatment of maladaptive neurohormonal activation in congestive heart failure (CHF) has been successful because basic cardiovascular science findings have been confirmed or dismissed through the use of well-controlled, large-scale clinical trials. It should be no surprise that this exciting approach is evolving toward novel agents and devices directed toward other pathways involved in CHF neurohormonal/cytokine activation. Several of these are in advanced clinical development and are likely to play prominent roles in CHF therapy in the near future.
authors.affiliation: Cardiology Section of the Department of Medicine, Gazes Cardiac Research Institute, Medical University of South Carolina, Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina, USA.
authors.forename: T X
authors.initials: TX
authors.lastname: O'Brien
authors.forename: A M
authors.initials: AM
authors.lastname: Brown
mesh_terms: D057911:Angiotensin Receptor Antagonists; D002304:Cardiac Pacing, Artificial; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014667:Vasopressins / Q000037:antagonists & inhibitors
chemical_list: D057911:Angiotensin Receptor Antagonists; D014409:Tumor Necrosis Factor-alpha; D014667:Vasopressins